Abstract Sacubitril/valsartan (S/V) is a new drug which has been recently recommended by
the international guidelines for the treatment of patients with chronic heart failure (HF) with …

Sacubitril with valsartan (sacubitril/valsartan) is a relatively novel compound that has
become a milestone in the treatment of patients with chronic heart failure (HF) with reduced …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the
cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades …

Since initial publication of the PARADIGM‐HF trial in 2014, sacubitril/valsartan has been
investigated in various settings to establish optimal use, further expanding its indications in …

Aims The study aims to explore the real‐world titration patterns of sacubitril/valsartan in a
chronic heart failure (HF) follow‐up management system and the effect on the recovery of …

Heart Failure (HF) is among the major causes of global morbidity as well as mortality.
Increased prevalence, frequent and prolonged hospitalization, rehospitalization, long-term …

Background: Sacubitril/valsartan improves heart failure (HF) outcomes in patients with heart
failure with reduced ejection fraction (HFrEF). However, randomized controlled trials (RCTs) …

Objective Heart failure with preserved ejection fraction (HFpEF) is a prevalent and clinically
significant condition characterized by limited treatment options. In this context, the objective …

There are an estimated 17.9 million people worldwide who have heart failure, despite the
widespread use of guideline-directed medical therapies such as angiotensin-converting …